ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $7.13B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 15.77M
Average 16.40M
IBRX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
ImmunityBio, Inc.NASDAQ: IBRX
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses remains negative
Q3 FY2026 other income / expenses was -$106.58M, compared with -$11.68M a year earlier. Trailing-twelve-month other income / expenses was -$835.68M.
Context
- Other income / expenses amounted to 84.4% of revenue in FY2025, down 386.7 pp from a year earlier.
- Other income / expenses grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$106.58M or moves back toward the trailing-twelve-month quarterly average of -$208.92M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (95.58M) USD
- Year-over-year change
- -37.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (95.58M) | -37.6% |
| FY2024 | 2024-12-31 | (69.46M) | +68.7% |
| FY2023 | 2023-12-31 | (221.64M) | -235.9% |
| FY2022 | 2022-12-31 | (65.99M) | -237.4% |
| FY2021 | 2021-12-31 | (19.56M) | — |
Other Income / Expenses vs competitors
How IBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -850.2% is the lowest of 11, against a peer median of -34.5%.
- Other income / expenses amounts to 457.7% of revenue for IBRX, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €260.88M EUR | -46.5% | — | 9.9% | |
| LTM Sep 2026 | $201M USD | -35.2% | +25.4% | 8.0% | |
| LTM Mar 2026 | $21.54M USD | -13.2% | +29.7% | 5.6% | |
| LTM Mar 2026 | $19.31M USD | -71.4% | — | 29.5% | |
| LTM Mar 2026 | $16.46M USD | -3.2% | — | — | |
| LTM Mar 2026 | $16.38M USD | -21.0% | +49.6% | — | |
| LTM Sep 2026 | $8.6M USD | -33.8% | +20.0% | 2.3% | |
| LTM Sep 2026 | -$1.9M USD | +94.1% | — | 0.1% | |
| LTM Mar 2026 | -€2.64M EUR | -106.2% | — | 7.1% | |
| LTM Mar 2026 | -$3.13M USD | -36.7% | — | 13.5% | |
| LTM Sep 2026 | -$835.68M USD | -850.2% | — | 457.7% | |
| Peer median (excluding IBRX) | — | -34.5% | +27.6% | 7.5% | |
Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 934K | 240K | 622K | 14.75M | 113.29M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 753K |
| Gross Profit | 934K | 240K | 622K | 14.75M | 112.54M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% |
| Research & Development | 195.96M | 248.15M | 232.37M | 190.14M | 207.88M |
| Selling, General & Admin | 135.26M | 102.71M | 129.62M | 168.78M | 147.18M |
| Operating Expenses | 331.21M | 351.54M | 362.87M | 358.93M | 368.56M |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| EBITDA | (320.75M) | (351.88M) | (478.66M) | (264.43M) | (223.56M) |
| EBITDA Margin | -34341.8% | -146617.1% | -76955.5% | -1793.4% | -197.3% |
| Operating Income | (330.28M) | (351.3M) | (362.25M) | (344.18M) | (256.03M) |
| Operating Margin | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| Interest Income | 836K | 2.71M | 863K | 2.4M | 6.7M |
| Interest Expense | 14.85M | 47.15M | 86.72M | 131.66M | 112.53M |
| Other Income / Expenses | (19.56M) | (65.99M) | (221.64M) | (69.46M) | (95.58M) |
| Income Before Tax | (349.84M) | (417.29M) | (583.89M) | (413.65M) | (351.61M) |
| Pre-Tax Margin | -37456.0% | -173869.2% | -93873.3% | -2805.3% | -310.4% |
| Income Tax Expense | 9K | 34K | (40K) | 0 | (135K) |
| Net Income | (346.79M) | (416.57M) | (583.2M) | (413.56M) | (351.4M) |
| Net Margin | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| EPS (Basic) | (0.89) | (1.04) | (1.15) | (0.59) | (0.38) |
| EPS (Diluted) | (0.89) | (1.04) | (1.15) | (0.62) | (0.38) |
| Weighted Avg Shares | 389.23M | 399.9M | 508.64M | 697.31M | 919.86M |
| Weighted Avg Shares (Diluted) | 389.23M | 399.9M | 508.64M | 700.44M | 919.86M |
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.